News | February 13, 2021
Jubilant Pharmova recovers: ICICI Securities
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
